{"id":"cisplatin-mitomycin-c-doxifluridine","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (neutropenia, thrombocytopenia)"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Ototoxicity"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Cisplatin is a platinum-based alkylating agent that cross-links DNA strands, preventing replication. Mitomycin-C is a mitomycin antibiotic that alkylates DNA and generates reactive oxygen species. Doxifluridine is a fluoropyrimidine that inhibits thymidylate synthase and gets incorporated into DNA/RNA, disrupting nucleotide synthesis. Together, these agents provide multi-modal cytotoxic activity against rapidly dividing cancer cells.","oneSentence":"This is a combination chemotherapy regimen that uses three cytotoxic agents to damage cancer cell DNA and inhibit cell division.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:06:05.089Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastric cancer (phase 3 trial context)"}]},"trialDetails":[{"nctId":"NCT00296322","phase":"PHASE3","title":"Trial of Adjuvant Chemotherapy for Gastric Cancer","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2001-10","conditions":"Stomach Cancer","enrollment":528},{"nctId":"NCT00296335","phase":"PHASE3","title":"Trial of Adjuvant Chemotherapy for Gastric Cancer","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2002-02","conditions":"Stomach Cancer","enrollment":855}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"cisplatin, mitomycin-C, doxifluridine","genericName":"cisplatin, mitomycin-C, doxifluridine","companyName":"Asan Medical Center","companyId":"asan-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a combination chemotherapy regimen that uses three cytotoxic agents to damage cancer cell DNA and inhibit cell division. Used for Gastric cancer (phase 3 trial context).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}